The bone formation inhibitor sclerostin encoded by SOST binds in vitro to low density lipoprotein receptor-related protein (LRP) 
Introduction Wnt/ß-catenin signaling/canonical Wnt signaling plays a key role in many physiological and pathological conditions. In bone, Wnt/ß-catenin signaling is required for commitment of mesenchymal stem cells to the osteogenic lineage, controls osteoblast precursor proliferation, differentiation and survival, but also osteoclastic bone resorption (1) (2) (3) (4) . It is initiated upon binding of secreted Wnt ligands to a dual-receptor complex formed by the frizzled (Fzd) receptor and the low density lipoprotein receptor-related protein 5 or 6 (LRP5/6) triggering a cascade of downstream signaling events, which results in accumulation of the central Wnt signaling effector ß-catenin and Wnt target gene expression.
Consistent with a central role of Wnt/ß-catenin signaling in bone metabolism LRP5 loss-offunction in humans causes the autosomal recessive Osteoporosis-pseudoglioma (OPPG) syndrome characterized by ocular abnormalities and low bone mass due to decreased bone formation (5) . This phenotype is recapitulated in Lrp5 deficient (Lrp5 -/-) mice (6, 7) . Similarly, mutations in Lrp6/LRP6 as well as osteoblast-specific deletion of Lrp5 or Lrp6 have been found to lead to reduced bone mass and osteoporosis in mice and humans (6, (8) (9) (10) . Conversely, autosomal dominant gain-of-function mutations in Lrp5/LRP5 lead to high bone mass (HBM) in mice and humans as a result of increased bone formation (11) (12) (13) .
Loss-of-function mutations in genes encoding the secreted Wnt signaling antagonists Dickkopf1 (DKK1/Dkk1) (14) and SOST/sclerostin also result in HBM-like phenotypes. Mutations in SOST cause the severe bone overgrowth disorders sclerosteosis (15, 16) , van Buchem disease (VBD) (17) (18) (19) and autosomal dominant craniodiaphyseal dysplasia (CDD) (20) . Likewise, Sost loss-of-function (Sost -/-) mice show elevated osteoblastic bone formation causing abnormal bone accumulation (21) .
Intriguingly, sclerostin and DKK1 binding to LRP5 is diminished in LRP5 gain-of-function mutants providing a mechanistic link for the observed HBM phenotypes (12, (22) (23) (24) (25) . 4 Sclerostin is a secreted glycoprotein, which in vitro causes inhibition of Wnt/ß-catenin signaling (24, (26) (27) (28) by binding to the first of four YWTD-type β-propeller domains in the extracellular domain of LRP5/6 thereby disrupting the formation of the Wnt ligand-receptor complex (29) (30) (31) . In addition, a facilitator of sclerostin's inhibitory action on Wnt/ß-catenin signaling, the LRP family member LRP4, was recently identified (32) . Like SOST deficiency, loss-of-function of LRP4 results in bone overgrowth in humans (32) . Given the crucial role of sclerostin as a negative bone formation regulator pharmacological interventions blocking its activity are under investigation to develop novel therapeutic agents for treatment of osteoporosis (33) . Understanding SOST/sclerostin mode of action in vivo is thus of great interest to develop novel therapies for skeletal disorders. In particular, it remains to be shown in vivo whether SOST/sclerostin targets LRP5 and/or LRP6 or also interacts with other signaling molecules to exert its function as a bone formation inhibitor.
To elucidate the in vivo mechanism of action of Sost, we generated (30) to assess the in vivo relevance of Lrp6 for Sost deficiency-induced bone anabolism. We provide some surprising insights into the mechanism of Wnt signaling in bone implicating novel therapeutic opportunities for patients with OPPG and rare sclerosing bone disorders through use of selective Wnt signaling modulators.
Materials and Methods

Mice
Sost -/- (34) and Lrp5 -/-(7) mice were previously described and were crossed to generate wild-type, Sost 
μCT measurements
Generation of 3D bone reconstruction images and evaluation of bone structure parameters was accomplished by high resolution ex vivo measurements using a vivaCT40 instrument (Scanco Medical AG; voxel size: 6 μm for anti-Lrp6 antibody experiments or else 10.5 μm). Thresholds of 225 for antibody experiments or 230 for genetic interaction studies were applied to determine the mineralized bone fraction. A Gaussian filter was used (σ = 0.7, support = 1) to remove noise. For antibody 6 experiments 60 or 65 vertebral and 60 or 80 femoral slices were evaluated and 85 slices were analyzed otherwise.
Serum biomarker measurements
Animals were sacrificed by terminal CO 2 exposure and whole blood was collected by venipuncture in case of anti-Lrp6 antibody experiments or else heart puncture. Serum was prepared using clot activator centrifugation tubes (Sarstedt). Osteocalcin was quantified with an immunoradiometric assay kit (Immutopics) and TRAP 5b was determined by ELISA (Immunodiagnostic Systems). Serotonin was measured in serum from day-fasted animals by HPLC. Serum was suspended in 10 volumes (v/w) of 0.1 N perchloric acid/0.05% disodium EDTA/0.05% sodium metabisulfite and serotonin was extracted.
10-µl samples were applied onto a Beckman Ultrasphere 5-µm IP column (Beckman) and eluted serotonin was quantified electrochemically at 0.65 V.
Bone histomorphometry
Mice received fluorochrome markers applied subcutaneously 10 (20 mg/kg alizarin complexone, Merck) and 3 days prior to necropsy (30 mg/kg calcein, Fluka). Bone samples were fixed for 24 hours in 4% phosphate-buffered paraformaldehye, dehydrated and defattened at 4°C and embedded in methylmethacrylate. A set of 5-μm non-consecutive longitudinal sections was cut in the frontal midbody plane per bone and animal. Fluorochrome marker-based dynamic bone parameters were determined using a Leica DM microscope fitted with a SONY DXC-950P camera and adapted Quantimet 600 software (Leica). Microscopic images were digitized and evaluated semi-automatically on screen (200-fold magnification) as previously described (35) . derived. Osteoclast numbers per bone surface were measured on sections stained for TRAP 5b activity using a Merz grid. Bone histomorphometric nomenclature was applied as recommended by the American society for bone and mineral research (36) .
Anti-Lrp6 antibody treatment
3-month-old female mice were subjected to one-month treatment with weekly intravenous injections of 10 mL/kg vehicle (PBS, pH 7.4, Invitrogen) or either of three anti-Lrp6 antibodies. Antibody A corresponding to the previously described antibody A7-IgG (30) was administered once weekly at 3 mg/kg. Antibody B equivalent to the previously reported antibody B2-IgG (30) was injected once weekly at 10 mg/kg. The biparatopic antibody A/B corresponding to the previously published antibody A7/B2 (30) was applied twice weekly at 3 mg/kg. These administered doses were chosen based on pharmacokinetics and pharmacodynamics studies to provide maximum exposure of these antibodies (30) . Various doses were tested and the doses above were determined to be maximum efficacious doses for each antibody. Dosing schedule was chosen based on the half-life of these antibodies in circulation.
Mice were assigned to treatment groups according to baseline cross-sectional total and cancellous BMD in the proximal tibia metaphysis as measured by pQCT as first and second rank parameter, respectively, as well as body weight as third rank parameter to ensure comparable group means and standard variations at baseline to minimize experimental artifacts.
qPCR expression analyses
Total RNA isolated from cortical bone of femoral diaphyses by sequential enzymatic digestion as previously described (37) was reverse transcribed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was determined using an ABI Prism 7900HT sequence detection system, TaqMan® Universal PCR Master Mix and the following mouse TaqMan® probes
(Mm01227479_m1) and Lrp6 (Mm00521783_m1).
Statistical analyses
All data represent the mean with standard error of the mean (SEM). Statistical analyses were performed with GraphPad Prism software using one-way analysis of variance (ANOVA) with Tukey's multiple comparisons post-hoc test or two-way ANOVA followed by Sidak's or Tukey's multiple comparisons post-hoc test as recommended by the software. 
Results
Reversal of
S1, A to D).
To determine the bone phenotypic consequences of Sost deletion in the Lrp5 -/-genetic background we monitored bone gain in the proximal tibia by longitudinal peripheral quantitative computed tomography (pQCT) during skeletal growth (2-and 3-month-old mice), maturity (4-monthold mice) and aging (6-month-old mice). Sost -/-mice displayed progressive strong increases in crosssectional total BMD and total bone mineral content, BMC (about +25% to +115% over time) relative to wild-type ( to D). However, during aging Lrp5 deficiency was not associated with significant differences relative to wild-type with the exception of total BMC, which remained significantly decreased in females by 34% ( Fig. 1 We next analyzed the distal femur using pQCT. Again, the Lrp5 -/-osteopenic phenotype was completely rescued, but there was a dramatic reduction of the relative Sost deficiency-induced bone gain in the cancellous and cortical bone compartment in Sost -/-;Lrp5 -/-mice ( Fig. 2 , E to G; Table 1 ).
Although slightly less pronounced, overall comparable findings were present in femora of 3-month-old mice ( Table 1) .
Blunting of Sost deficiency-induced increases in osteoblast function in absence of Lrp5
To determine the underlying mechanism of the reduced relative Sost deficiency-induced bone gain in
Sost -/-
;Lrp5 -/-mice we measured serum bone turnover markers and performed bone histomorphometry in 6-month-old mice. The bone resorption marker tartrate resistant acid phosphatase (TRAP) 5b was not significantly altered between genotypes (Table 2) . Similarly, analysis of lumbar vertebra L3 did not reveal significant differences in osteoclast number between genotypes ( (Fig. 3 , E to G).
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As sclerostin is known to not only bind to Lrp5, but also to the related Wnt co-receptor Lrp6, which might partially compensate for Lrp5 deficiency, we determined Lrp5/6 expression in femoral cortical bone using quantitative reverse transcription polymerase chain reaction (qPCR). Consistent with previously reported residual expression in Lrp5 -/-mice resulting in expression of a truncated peptide (7) , Lrp5 expression was still detectable in Lrp5 -/-and Sost -/-; Lrp5 -/-mice (Fig. S2A) .
Interestingly, we observed a mild upregulation of Lrp6 in Lrp5 -/-(females: +68%; males: +42%) and
Sost -/-
; Lrp5 -/-mice (females: +40%; males: +33%) relative to wild-type (Fig. S2B) , whereas Lrp5/6 expression was unchanged in Sost -/-littermates (Fig. S2) .
Reduction of Sost deficiency-induced bone gain in absence of Wnt1 class-mediated Lrp6 signaling in the axial and appendicular skeleton
To address the role of Lrp6 in Sost deficiency-induced bone anabolism, we subjected wild-type
and Sost -/-mice during late-stage skeletal growth to treatment with either of three distinct anti-Lrp6
antibodies with different modes of action (30) . Anti-Lrp6 antibody A was previously shown to bind to the first YWTD-type β-propeller in the extracellular domain of Lrp6 thereby selectively blocking Lrp6 signaling induced by binding of Wnt1 class ligands including Wnt1/2/6/7a/7b/9a/10a/10b (30) , while potentiating Wnt3-and Wnt3a-mediated Lrp6 activity. Conversely, anti-Lrp6 antibody B binds to the third β-propeller and exerts the reverse pattern of function. Finally, the engineered biparatopic antibody A/B potently inhibits both, Wnt1 and Wnt3/Wnt3a class-mediated Lrp6 signaling (Fig. 4F) .
Analysis of the proximal tibia by pQCT revealed that blocking Wnt1 class-mediated Lrp6 activity with antibody A strongly reduced the abnormal increase in cross-sectional total BMD in Sost -/-mice by 63%
over the four-week treatment period (Fig. 4A) . Consistently, Sost deficiency-induced gain in crosssectional cancellous BMD was diminished by 73% ( Fig. 4B ) and expansion of cortical thickness was reduced by 67% (Fig. 4C) . Moreover, blocking Wnt1 class-mediated Lrp6 activity in Sost -/-mice not 12 only robustly decreased Sost deficiency-induced enhanced bone gain, but resulted in bone gain that was comparable to the normal age-related late-stage skeletal growth in vehicle-treated wild-type mice with exception of cancellous BMD gain, which had already stopped at this age, but was present at a reduced level in antibody A-treated Sost -/-mice (Fig. 4B) . In contrast, normal skeletal growth-related bone gain in wild-type mice was mildly, but non-significantly reduced by inhibiting Wnt1 classmediated Lrp6 signaling (Fig. 4, A to C) . Importantly, the reduction in tibial bone growth in wild-type
and Sost -/-mice occurred irrespective of enhancement or blockage of Wnt3a class-mediated Lrp6 signaling (Fig. 4 , A to C). Consistently, promoting Wnt1 class-mediated Lrp6 activity in absence of Wnt3a class-mediated Lrp6 signaling induced by antibody B treatment resulted in a dramatic further enhancement of the abnormal bone increases in Sost -/-mice by about 3.2-fold in both bone compartments (Fig. 4 , A to C, Fig. 4E ). Likewise, normal bone growth in wild-type mice was also significantly augmented in both bone compartments by antibody B treatment (Fig. 4 , A to C).
However, the relative increases compared to vehicle-treated mice were about 30% smaller than in Sost -/-mice.
Next, we performed detailed bone structure analyses in the axial and appendicular skeleton using µCT. Consistent with the changes observed in the tibia, blocking Wnt1 class-mediated Lrp6 activity in Sost -/-and wild-type mice following either treatment with antibody A or A/B resulted in reductions of BMD and relative bone volume in the spine and smaller non-significant decreases in the femur (Table 3 ; Fig. 4D ). These decreases in cancellous bone density and mass were associated with selective reductions in trabecular number (Table 3) . Conversely, stimulating Wnt1 class-mediated Lrp6 activity in presence of blocked Wnt3a-mediated Lrp6 signaling by antibody B treatment further enhanced the abnormal vertebral and femoral bone gain in Sost -/-mice by about 1.3-to 2-fold for most parameters analyzed (Table 3 ; Fig. 4D ). The same treatment in wild-type mice caused only nonsignificant changes. 13 We then determined serum osteocalcin levels. Treatment with antibodies blocking Wnt1 classmediated Lrp6 activity suppressed osteocalcin concentration weakly, but non-significantly by 20-30%
relative to vehicle-treated mice of either genotype (Fig. S3) . Conversely, antibody B treatment nonsignificantly increased osteocalcin by 25% in Sost -/-mice, whereas it was non-significantly reduced by 31% in wild-type mice (Fig. S3) . showed significant decreases in these parameters compared to vehicle-treated mice ( (Table 4) .
Loss of Sost deficiency-induced bone gain in absence of
Finally, to further address the relative differences in sensitivity between genotypes towards altered Wnt1 class-versus Wnt3a class-mediated Lrp6 signaling, we measured expression of the Wnt signaling inhibitor Dkk1 in femoral cortical bone in response to vehicle or antibody A treatment. In contrast to sclerostin, which selectively binds to the first YWTD-type β-propeller of LRP6, Dkk1 also interacts with the third β-propeller antagonizing both Wnt1 class-and Wnt3a class-induced Lrp6 activity (38, 39) . Interestingly, in vehicle-treated animals Dkk1 expression was strongly upregulated in 15 In line with this interpretation, previous data indicate that sclerostin also targets factors other than Lrp5 or that compensatory mechanisms exist to functionally substitute for loss of Lrp5.
Interestingly, mice lacking one or both alleles of Lrp5 and just one copy of Lrp6 constitutively display gene dosage dependent limb deformities and decreased bone mineral density (BMD) suggesting that Lrp5/6 serve partially redundant functions in embryonic as well as adult bone (6) . In addition, single and combined osteoblast-specific deletion of Lrp5 and Lrp6 in mice revealed overlapping functions of both receptors in osteoblasts and postnatal bone acquisition (10) . Similarly, Sost and Lrp6 have been shown to genetically interact during skeletal development (40) and recent in vitro data have identified LRP6 as the main sclerostin receptor in mesenchymal cells (41) supporting our findings that Sost deficiency-induced bone anabolism largely depends on Wnt1 ligand-induced Lrp6 activity.
Sost deficiency-induced bone gain was reversed to levels of normal late-stage skeletal growth by blockage of Wnt1 class-induced Lrp6 activity in the cortical but not cancellous bone compartment, as cancellous bone gain although reduced remained slightly elevated compared to wild-type mice.
Whether additional pathways such as the bone morphogenetic protein (BMP) signaling pathway (16, 28, 42, 43) or other targets interacting with sclerostin (44, 45) contribute to Sost deficiency-induced bone anabolism in the cancellous bone compartment remains to be addressed.
Given that the Lrp5 loss-of-function bone phenotype was suggested to be caused by a bone independent role of Lrp5 controlling serotonin biosynthesis in the duodenum (46) , we also determined serum serotonin levels. Opposed to previously reported elevated serum serotonin in the present Lrp5
-/-mouse model, we failed to detect differences between genotypes (Fig. S4 ) consistent with recent data demonstrating a local role of Lrp5 in bone (47) . LRP5/6 are highly homologous Wnt co-receptors of the LRP receptor family that are coexpressed in many developing and adult tissues with overlapping function (48) . Structural data revealed that sclerostin binds to LRP6 through a conserved interaction motif present in the first YWTD-type β- 16 propeller of the extracellular domain of LRP5/6 thereby causing inhibition of Wnt1 but not Wnt3a class-induced signaling (29) (30) (31) . Consequently, inhibiting Lrp6 activity induced by Wnt1 class ligands including Wnt1/2/6/7a/7b/9a/10a/10b (30) (26, (49) (50) (51) (52) (53) (54) (55) (56) . Nevertheless, WNT3a polymorphisms are associated with human BMD variation (57) and rare inherited variants of WNT3a with reduced signaling activity have been identified in patients with childhood-onset primary osteoporosis (58) .
Given the importance of Wnt/β-catenin signaling for adult bone homeostasis, various therapeutic approaches are being developed to target this bone anabolic pathway aiming at increasing bone mass in conditions of bone fragility (33, 59) . Novel therapeutic agents such as neutralizing antisclerostin antibodies are in clinical development with promising results in a first-in-human study (60) .
Our data suggest that patients suffering from LRP5 loss-of-function causing the debilitating disease OPPG with severely decreased skeletal mass and strength should benefit from therapeutic principles 17 blocking SOST/sclerostin activity given that Lrp5 deficiency-induced osteopenia was fully reversed upon Sost loss-of-function. There is a clear medical need in this rare genetic disorder of decreased BMD and elevated fracture risk as only some, but not all OPPG patients respond to currently available treatment options (61, 62) .
In addition, our data suggest that patients suffering from severe bone overgrowth associated with decreased SOST function as in sclerosteosis, VBD and CDD might profit from therapeutic WNT signaling antagonists, given that the abnormal bone gain in Sost -/-mice was normalized upon blockage of Wnt1 class-mediated Lrp6 activity. Currently, the only available treatment for SOST-related sclerosing bone dysplasias consists in repeated surgical intervention for bone removal illustrating the medical need in these rare diseases. Similarly, therapeutic WNT signaling inhibitors might be beneficial for treatment of other rare skeletal hyperostosis disorders including bone dysplasias related to LRP4 loss-of-function mutations, which disrupt the LRP4-sclerostin interaction and associated LRP4 facilitator effect on sclerostin function (32) . Several approaches to inhibit WNT/β-catenin signaling are presently being investigated some of which having progressed to early clinical development for treatment of cancer-related indications after promising preclinical results. These range from function blocking anti-LRP6 antibodies (30, 63) , to Fzd receptor antagonists such as the anti-Fzd antibody vantictumab (64) , to small molecule inhibitors of porcupine, a membrane bound Oacyltransferase required for WNT ligand secretion and activity, and tankyrase inhibitors causing axin stabilizing and β-catenin degradation (65) . However, given the pleiotropic nature of WNT/ß-catenin signaling treatment-related adverse effects need to be taken into account, especially in non-oncogenic clinical settings. Nevertheless, careful assessment of safety and therapeutic potential of WNT signaling antagonists in sclerosing bone dysplasias might reveal therapeutic windows and uncover novel therapeutic strategies to overcome the medical need in these devastating skeletal diseases. 18 In conclusion, our data highlight the potential for novel drug targeting approaches in rare skeletal disorders ranging from severe skeletal fragility to sclerosing bone overgrowth through selective modulation of canonical WNT signaling. These approaches should also be beneficial in the context of other medical conditions with much less severe phenotypes such as postmenopausal osteoporosis given the crucial role of this potent bone anabolic pathway for skeletal homeostasis (59) . Group size: n = 6-13 (females), n = 3-12 (males Statistical significance determined by one-way ANOVA is designated as follows: *, p < 0.05; **, p < Table 3 . Ex vivo µCT determination of bone structure indices in lumbar vertebra L3 and the distal femur metaphysis after one-month treatment with distinct anti-Lrp6 antibodies. Table 4 . Ex vivo µCT determination of bone structure indices in lumbar vertebra L3 and the distal femur metaphysis after one-month treatment with anti-Lrp6 antibody A suppressing Wnt1 and promoting Wnt3a class-mediated Lrp6 signaling. 
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